Targeting Notch1 signaling pathway positively affects the sensitivity of osteosarcoma to cisplatin by regulating the expression and/or activity of Caspase family

详细信息    查看全文

• 作者：Lei Wang (1)
  Fangchun Jin (1)
  An Qin (1)
  Yongqiang Hao (1)
  Yufeng Dong (2)
  Shengfang Ge (3)
  Kerong Dai (1)
  
  1. Department of Orthopaedics ; Ninth People鈥檚 Hospital ; Shanghai JiaoTong University School of Medicine ; 639 Zhizaoju Road ; Shanghai ; 200011 ; People鈥檚 Republic of China
  2. Department of Orthopaedics and Rehabilitation ; Center for Musculoskeletal Research ; University of Rochester School of Medicine and Dentistry ; Rochester ; NY ; 14642 ; USA
  3. Department of Ophthalmology ; Ninth People鈥檚 Hospital ; Shanghai JiaoTong University School of Medicine ; 639 Zhizaoju Road ; Shanghai ; 200011 ; People鈥檚 Republic of China
  
• 关键词：Osteosarcoma ; Notch1 signaling pathway ; Targeting regulation ; Cisplatin sensitivity ; Caspase family
• 刊名：Molecular Cancer
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：13
• 期：1
• 全文大小：2,792 KB
• 参考文献：1. Mirabello, L, Troisi, RJ, Savage, SA (2009) International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer 125: pp. 229-234 CrossRef
  2. Franchi, A (2012) Epidemiology and classification of bone tumors. Clin Cases Miner Bone Metab 9: pp. 92-95
  3. Eyre, R, Feltbower, RG, Mubwandarikwa, E, Eden, TO, McNally, RJ (2009) Epidemiology of bone tumours in children and young adults. Pediatr Blood Cancer 53: pp. 941-952 CrossRef
  4. Bacci, G, Longhi, A, Fagioli, F, Briccoli, A, Versari, M, Picci, P (2005) Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27聽year experience at Rizzoli Institute, Italy. Eur J Cancer 41: pp. 2836-2845 CrossRef
  5. Link, MP, Goorin, AM, Miser, AW, Green, AA, Pratt, CB, Belasco, JB, Pritchard, J, Malpas, JS, Baker, AR, Kirkpatrick, JA, Ayala, AG, Shuster, JJ, Abelson, HT, Simone, JV, Vietti, TJ (1986) The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 314: pp. 1600-1606 CrossRef
  6. Rosen, G, Caparros, B, Huvos, AG, Kosloff, C, Nirenberg, A, Cacavio, A, Marcove, RC, Lane, JM, Mehta, B, Urban, C (1982) Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 49: pp. 1221-1230 CrossRef
  7. Abe, S, Nishimoto, Y, Isu, K, Ishii, T, Goto, T (2002) Preoperative cisplatin for initial treatment of limb osteosarcoma: its local effect and impact on prognosis. Cancer Chemother Pharmacol 50: pp. 320-324 CrossRef
  8. Anninga, JK, Gelderblom, H, Fiocco, M, Kroep, JR, Taminiau, AH, Hogendoorn, PC, Egeler, RM (2011) Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand?. Eur J Cancer 47: pp. 2431-2445 CrossRef
  9. Ozols, RF, Young, RC (1991) Chemotherapy of ovarian cancer. Semin Oncol 18: pp. 222-232
  10. Dancey, J, Le Chevalier, T (1997) Non-small cell lung cancer: an overview of current management. Eur J Cancer 33: pp. S2-S7 CrossRef
  11. Bacci, G, Ruggieri, P, Picci, P, Mercuri, M, Ferraro, A, Tella, G, Ferrari, S, Bertoni, F, Comandone, A (1996) Intra-arterial versus intravenous cisplatinum (in addition to systemic Adriamycin and high dose methotrexate) in the neoadjuvant treatment of osteosarcoma of the extremities. results of a randomized study. J Chemother 8: pp. 70-81 CrossRef
  12. Jaffe, N, Knapp, J, Chuang, VP, Wallace, S, Ayala, A, Murray, J, Cangir, A, Wang, A, Benjamin, RS (1983) Osteosarcoma: intra-arterial treatment of the primary tumor with cis-diammine-dichloroplatinum II (CDP). Angiographic, pathologic, and pharmacologic studies. Cancer 51: pp. 402-407 CrossRef
  13. Jaffe, N (1993) Pediatric osteosarcoma: treatment of the primary tumor with intraarterial cis-diamminedichloroplatinum-II (CDP)鈥揳dvantages, disadvantages, and controversial issues. Cancer Treat Res 62: pp. 75-84 CrossRef
  14. Yuan, JM, Li, XD, Liu, ZY, Hou, GQ, Kang, JH, Huang, DY, Du, SX (2011) Cisplatin induces apoptosis via upregulating Wrap53 in U-2OS osteosarcoma cells. Asian Pac J Cancer Prev 12: pp. 3465-3469
  15. Chou, AJ, Gorlick, R (2006) Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther 6: pp. 1075-1085 CrossRef
  16. Miele, L (2006) Notch signaling. Clin Cancer Res 12: pp. 1074-1079 CrossRef
  17. Chiba, S (2006) Notch signaling in stem cell systems. Stem Cells 24: pp. 2437-2447 CrossRef
  18. Dong, Y, Jesse, AM, Kohn, A, Gunnell, LM, Honjo, T, Zuscik, MJ, O鈥橩eefe, RJ, Hilton, MJ (2010) RBPjkappa-dependent Notch signaling regulates mesenchymal progenitor cell proliferation and differentiation during skeletal development. Development 137: pp. 1461-1471 CrossRef
  19. Villanueva, A, Alsinet, C, Yanger, K, Hoshida, Y, Zong, Y, Toffanin, S, Rodriguez-Carunchio, L, Sol茅, M, Thung, S, Stanger, BZ, Llovet, JM (2012) Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. Gastroenterology 143: pp. 1660-1669 CrossRef
  20. Ueo, T, Imayoshi, I, Kobayashi, T, Ohtsuka, T, Seno, H, Nakase, H, Chiba, T, Kageyama, R (2012) The role of Hes genes in intestinal development, homeostasis and tumor formation. Development 139: pp. 1071-1082 CrossRef
  21. Weng, AP, Lau, A (2005) Notch signaling in T-cell acute lymphoblastic leukemia. Future Oncol 1: pp. 511-519 CrossRef
  22. Qiao, L, Wong, BC (2009) Role of Notch signaling in colorectal cancer. Carcinogenesis 30: pp. 1979-1986 CrossRef
  23. Engin, F, Bertin, T, Ma, O, Jiang, MM, Wang, L, Sutton, RE, Donehower, LA, Lee, B (2009) Notch signaling contributes to the pathogenesis of human osteosarcomas. Hum Mol Genet 18: pp. 1464-1470 CrossRef
  24. Wang, Z, Li, Y, Ahmad, A, Azmi, AS, Banerjee, S, Kong, D, Sarkar, FH (2010) Targeting Notch signaling pathway to overcome drug resistance for cancer therapy. Biochim Biophys Acta 1806: pp. 258-267
  25. Geller, DS, Gorlick, R (2010) Osteosarcoma: a review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol 8: pp. 705-718
  26. Ferguson, WS, Goorin, AM (2001) Current treatment of osteosarcoma. Cancer Invest 19: pp. 292-315 CrossRef
  27. Meyers, PA, Schwartz, CL, Krailo, M, Kleinerman, ES, Betcher, D, Bernstein, ML, Conrad, E, Ferguson, W, Gebhardt, M, Goorin, AM, Harris, MB, Healey, J, Huvos, A, Link, M, Montebello, J, Nadel, H, Nieder, M, Sato, J, Siegal, G, Weiner, M, Wells, R, Wold, L, Womer, R, Grier, H (2005) Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 23: pp. 2004-2011 CrossRef
  28. Bruheim, S, Xi, Y, Ju, J, Fodstad, O (2009) Gene expression profiles classify human osteosarcoma xenografts according to sensitivity to doxorubicin, cisplatin, and ifosfamide. Clin Cancer Res 15: pp. 7161-7169 CrossRef
  29. Tanaka, M, Setoguchi, T, Hirotsu, M, Gao, H, Sasaki, H, Matsunoshita, Y, Komiya, S (2009) Inhibition of Notch pathway prevents osteosarcoma growth by cell cycle regulation. Br J Cancer 100: pp. 1957-1965 CrossRef
  30. Zhang, P, Yang, Y, Zweidler-McKay, PA, Hughes, DP (2008) Critical role of notch signaling in osteosarcoma invasion and metastasis. Clin Cancer Res 14: pp. 2962-2969 CrossRef
  31. Gu, F, Ma, Y, Zhang, Z, Zhao, J, Kobayashi, H, Zhang, L, Fu, L (2010) Expression of Stat3 and Notch1 is associated with cisplatin resistance in head and neck squamous cell carcinoma. Oncol Rep 23: pp. 671-676
  32. Zhang, S, Balch, C, Chan, MW, Lai, HC, Matei, D, Schilder, JM, Yan, PS, Huang, TH, Nephew, KP (2008) Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 68: pp. 4311-4320 CrossRef
  33. Nicolas, M, Wolfer, A, Raj, K, Kummer, JA, Mill, P, van Noort, M, Hui, CC, Clevers, H, Dotto, GP, Radtke, F (2003) Notch1 functions as a tumor suppressor in mouse skin. Nat Genet 33: pp. 416-421 CrossRef
  34. Viatour, P, Ehmer, U, Saddic, LA, Dorrell, C, Andersen, JB, Lin, C, Zmoos, AF, Mazur, PK, Schaffer, BE, Ostermeier, A, Vogel, H, Sylvester, KG, Thorgeirsson, SS, Grompe, M, Sage, J (2011) Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway. J Exp Med 208: pp. 1963-1976 CrossRef
  35. Hilton, MJ, Tu, X, Wu, X, Bai, S, Zhao, H, Kobayashi, T, Kronenberg, HM, Teitelbaum, SL, Ross, FP, Kopan, R, Long, F (2008) Notch signaling maintains bone marrow mesenchymal progenitors by suppressing osteoblast differentiation. Nat Med 14: pp. 306-314 CrossRef
  36. Oldershaw, RA, Tew, SR, Russell, AM, Meade, K, Hawkins, R, McKay, TR, Brennan, KR, Hardingham, TE (2008) Notch signaling through Jagged-1 is necessary to initiate chondrogenesis in human bone marrow stromal cells but must be switched off to complete chondrogenesis. Stem Cells 26: pp. 666-674 CrossRef
  37. Oldershaw, RA, Hardingham, TE (2010) Notch signaling during chondrogenesis of human bone marrow stem cells. Bone 46: pp. 286-293 CrossRef
  38. Engin, F, Yao, Z, Yang, T, Zhou, G, Bertin, T, Jiang, MM, Chen, Y, Wang, L, Zheng, H, Sutton, RE, Boyce, BF, Lee, B (2008) Dimorphic effects of Notch signaling in bone homeostasis. Nat Med 14: pp. 299-305 CrossRef
  
• 刊物主题：Cancer Research; Oncology;
• 出版者：BioMed Central
• ISSN：1476-4598

文摘

Background The introduction of cisplatin has improved the long-term survival rate in osteosarcoma patients. However, some patients are intrinsically resistant to cisplatin. This study reported that the activation of Notch1 is positively correlated with cisplatin sensitivity, evidenced by both clinical and in vitro data. Results In this study, a total 8 osteosarcoma specimens were enrolled and divided into two groups according to their cancer chemotherapeutic drugs sensitivity examination results. The relationship between Notch1 expression and cisplatin sensitivity of osteosarcoma patients was detected by immunohistochemistry and semi-quantitative analysis. Subsequently, two typical osteosarcoma cell lines, Saos-2 and MG63, were selected to study the changes of cisplatin sensitivity by up-regulating (NICD1 plasmid transfeciton) or decreasing (gamma-secretase complex inhibitor DAPT) the activation state of Notch1 signaling pathway. Our results showed a significant correlation between the expression of Notch1 and cisplatin sensitivity in patient specimens. In vitro, Saos-2 with higher expression of Notch1 had significantly better cisplatin sensitivity than MG63 whose Notch1 level was relatively lower. By targeting regulation in vitro, the cisplatin sensitivity of Saos-2 and MG63 had significantly increased after the activation of Notch1 signaling pathway, and vice versa. Further mechanism investigation revealed that activation/inhibition of Notch1 sensitized/desensitized cisplatin-induced apoptosis, which probably depended on the changes in the activity of Caspase family, including Caspase 3, Caspase 8 and Caspase 9 in these cells. Conclusions Our data clearly demonstrated that Notch1 is critical for cisplatin sensitivity in osteosarcoma. It can be used as a molecular marker and regulator for cisplatin sensitivity in osteosarcoma patients.